Phase II, Single-arm Study of Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification(SUKSE-D)
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Vistusertib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms SUKSES-D
- 04 Jun 2019 Results assessing efficacy of AZD1775, AZD2014, AZD2811 in 3 trials (NCT02593019, NCT03106155, NCT03366675), presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 18 Sep 2018 Status changed from recruiting to discontinued.
- 27 Sep 2017 Status changed from not yet recruiting to recruiting.